Literature DB >> 87927

Visual loss during oral diethylcarbamazine treatment for onchocerciasis.

A C Bird, H El-Sheikh, J Anderson, H Fuglsang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 87927     DOI： 10.1016/s0140-6736(79)90214-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  New Research Aims to Optimize Therapy Against Onchocerciasis.

Authors:  Augustine R Hong; Nicholas O Opoku; Gary J Weil; Eric M Kanza; Michael E Gyasi
Journal:  Mo Med       Date:  2022 Jan-Feb

2.  Treatment of filariasis-diethylcarbamazine and its congeners.

Authors:  S Sharma
Journal:  Pharm Res       Date:  1986-04       Impact factor: 4.200

3.  Current evidence on the use of antifilarial agents in the management of bancroftian filariasis.

Authors:  Sumadhya Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  J Trop Med       Date:  2010-12-30

4.  Diagnosis of O. volvulus infection via skin exposure to diethylcarbamazine: clinical evaluation of a transdermal delivery technology-based patch.

Authors:  K Awadzi; Nicholas O Opoku; Simon K Attah; Janis K Lazdins-Helds; Annette C Kuesel
Journal:  Parasit Vectors       Date:  2015-10-09       Impact factor: 3.876

5.  A murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasis.

Authors:  Alice Halliday; Ana F Guimaraes; Hayley E Tyrer; Haelly Mejane Metuge; Chounna Ndongmo Winston Patrick; Kengne-Ouafo Jonas Arnaud; Tayong Dizzle Bita Kwenti; George Forsbrook; Andrew Steven; Darren Cook; Peter Enyong; Samuel Wanji; Mark J Taylor; Joseph D Turner
Journal:  Parasit Vectors       Date:  2014-10-24       Impact factor: 3.876

6.  Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule.

Authors:  L Ceballos; L Alvarez; C Mackenzie; T Geary; C Lanusse
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-09-25       Impact factor: 4.077
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.